Enthorin Therapeutics

Executive Summary

Enthorin Therapeutics is a clinical-stage pharmaceutical company dedicated to developing innovative small-molecule therapeutics that target brain circuit dysfunction, aiming to improve quality of life for patients with neurological disorders. Founded in 2021 and headquartered in Cambridge, Massachusetts, the company was co-founded by Dr. J. Guy Breitenbucher, formerly Head of Discovery Chemistry at Dart Neuroscience. Enthorin is advancing a pipeline of preclinical and Phase 1 assets focused on modulating neural circuits to address conditions such as pain and other central nervous system disorders. The company’s approach leverages deep expertise in medicinal chemistry and neuroscience to create treatments with novel mechanisms of action. Despite being in early stages, Enthorin’s focus on brain circuit modulation positions it in a high-interest area of drug development, with potential to address unmet needs in neurology and psychiatry. The company is privately held and has not disclosed total funding, but its progression to Phase 1 indicates meaningful investor support.

Upcoming Catalysts (preview)

• Q2 2027Phase 1 Clinical Data Readout for Lead Program40% success
• Q4 2026Series B Financing Announcement60% success
• Q1 2028Initiation of Phase 2 Trial for Pain Indication35% success